NASDAQ : TVRD
Tvardi Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.863 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 11.51M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 10.58M |
| Enterprise Value | -5.04M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 13.34M |
| Shares Outstanding | 13.34M |
| Shares Change (YoY) | +134.87% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 16.31% |
| Owned by Institutions (%) | 18.99% |
| Float | 9.63M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.89 |
| P/TBV Ratio | 1.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.87 |
| Quick Ratio | 1.73 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -126.19% |
| Return on Assets (ROA) | -55.51% |
| Return on Invested Capital (ROIC) | -81.53% |
| Return on Capital Employed (ROCE) | -323.71% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.17M |
| Employee Count | 12 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | -83.41% |
| 50-Day Moving Average | 1.38 |
| 200-Day Moving Average | 2.76 |
| Relative Strength Index (RSI) | 27.07 |
| Average Volume (20 Days) | 128,547 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 375,939 |
| Short Previous Month | 224,403 |
| Short % of Shares Out | 2.82% |
| Short % of Float | 3.90% |
| Short Ratio (days to cover) | 1.65 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -27.21M |
| Pretax Income | -26.06M |
| Net Income | -26.06M |
| EBITDA | -27.11M |
| EBIT | -27.21M |
| Earnings Per Share (EPS) | -$2.77 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 15.77M |
| Total Debt | 145,000 |
| Net Cash | 15.62M |
| Net Cash Per Share | $1.17 |
| Equity (Book Value) | 8.38M |
| Book Value Per Share | 0.89 |
| Working Capital | 7.96M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -25.03M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 95,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -25.03M |
| FCF Per Share | -$1.88 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -134.87% |
| Shareholder Yield | -134.87% |
| Earnings Yield | -349.87% |
| FCF Yield | -236.68% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $9.63 |
| Price Target Difference | 1,114.05% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |